Abivax Establishes an At-the-Market (ATM) Program on Nasdaq
Portfolio Pulse from
Abivax SA, a clinical-stage biotechnology company, has established an At-the-Market (ATM) program on Nasdaq, allowing it to issue and sell ordinary shares in the form of American Depositary Shares (ADS) with gross sales proceeds up to $150 million. Piper Sandler & Co. will act as the sales agent.
November 19, 2024 | 9:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Abivax SA has initiated an ATM program on Nasdaq to raise up to $150 million through the sale of ADSs, with Piper Sandler as the sales agent.
The ATM program allows Abivax to raise capital by issuing ADSs, which could provide financial flexibility and support its operations. This is likely to be viewed positively by investors, potentially leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100